Table 2.

Patient outcomes

Outcome	Total (N = 938)	Non-responders (N = 512)	Responders (N = 426)	P value
In-hospital mortality, n (%)	608 (64.8)	367 (71.7)	241 (56.6)	< 0.001
ICU mortality, n (%)	561 (59.8)	347 (67.8)	214 (50.2)	< 0.001
ICU-free days at day 14	1.9 ± 3.6	1.6 ± 3.3	2.3 ± 3.8	< 0.001
Hospital-free days at day 28	3.4 ± 6.6	2.8 ± 6.0	4.2 ± 7.2	< 0.001
MV-free days at day 14	2.8 ± 4.9	2.2 ± 4.5	3.6 ± 5.3	< 0.001
SOFA score changea	0.6 ± 2.9	0.8 ± 2.9	0.3 ± 2.9	0.02
Respiration score change	2.3 ± 1.5	2.0 ± 1.5	2.5 ± 1.4	< 0.001
Coagulation score change	0.46 ± 1.0	0.5 ± 0.9	0.4 ± 1.0	0.19
Liver score change	0.1 ± 0.7	0.1 ± 0.8	0.7 ± 0.6	0.90
Neurological score change	− 0.1 ± 1.1	0.1 ± 1.1	− 0.2 ± 1.0	< 0.001
Cardiovascular score change	− 1.9 ± 1.7	− 1.6 ± 1.7	− 2.1 ± 1.7	< 0.001
CRRT initiation between AVP start and 72 h, n (%)b	190 (25.0)	112 (30.0)	78 (20.2)	0.002
CA dose changec, mcg/min	+1.7 ± 40.6	+13.8 ± 51.2	− 12.8 ± 9.6	< 0.001
CA-free days at day 14	5.0 ± 5.8	3.9 ± 5.5	6.3 ± 6.0	< 0.001

CA catecholamine, CRRT continuous renal replacement therapy, MV mechanical ventilation, SOFA sequential organ failure assessment

^aEvaluated at hour 48 after vasopressin initiation

^bEvaluated only in patients who survived at least 24 h after vasopressin initiation

^cEvaluated at hour 6 after vasopressin initiation